$-0.77 EPS Expected for Madrigal Pharmaceuticals, Inc. (MDGL); Ekso Bionics Holdings (EKSO) Sellers Decreased By 10.49% Their Shorts

April 17, 2018 - By Ellis Scott

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Logo

Analysts expect Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) to report $-0.77 EPS on May, 10.They anticipate $0.27 EPS change or 54.00% from last quarter’s $-0.5 EPS. After having $-0.67 EPS previously, Madrigal Pharmaceuticals, Inc.’s analysts see 14.93% EPS growth. The stock increased 2.94% or $3.4 during the last trading session, reaching $118.85. About 234,420 shares traded. Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has risen 574.52% since April 17, 2017 and is uptrending. It has outperformed by 562.97% the S&P500.

Ekso Bionics Holdings Inc (NASDAQ:EKSO) had a decrease of 10.49% in short interest. EKSO’s SI was 2.95 million shares in April as released by FINRA. Its down 10.49% from 3.30M shares previously. With 1.31 million avg volume, 2 days are for Ekso Bionics Holdings Inc (NASDAQ:EKSO)’s short sellers to cover EKSO’s short positions. The stock decreased 0.61% or $0.01 during the last trading session, reaching $1.63. About 100,914 shares traded. Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) has declined 54.18% since April 17, 2017 and is downtrending. It has underperformed by 65.73% the S&P500.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company has market cap of $1.69 billion. The company's lead candidate is MGL-3196, which is in Phase II clinical trials, a liver-directed thyroid hormone receptor-ß agonist used for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and familial hypercholesterolemia. It currently has negative earnings. It is also developing MGL-3745, which is in pre-clinical stage, a THR-ß agonist that is in preclinical trials.

Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company has market cap of $98.15 million. The firm operates through Medical Devices, Industrial Sales, and Engineering Services divisions. It currently has negative earnings. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Ellis Scott

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: